ストックスクリーナーアプリを入手
3.9145
4.26%
-0.0755
前日終値:
$3.99
開ける：
$3.91
24時間の取引高:
19,929
Relative Volume:
2.39
時価総額：
$4.84M
収益：
$2.54M
当期純損益:
$-4.13M
株価収益率:
-1.4235
EPS:
-2.75
ネットキャッシュフロー:
$-4.11M
1週間 パフォーマンス:
+37.41%
1か月 パフォーマンス:
+32.49%
6か月 パフォーマンス:
-7.04%
1年 パフォーマンス:
-7.95%
1日の値動き範囲:
$3.8587
$4.02
1週間の範囲:
$2.65
$5.2683
52週間の値動き範囲:
$2.20
$5.2683
Xenetic Biosciences Inc Stock (XBIO) Company Profile
名前
Xenetic Biosciences Inc
セクター
電話
781-778-7720
住所
945 CONCORD ST., FRAMINGHAM, MA
XBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.9117 | 4.84M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.12 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.62 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
239.94 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-08 | 開始されました | Maxim Group | Buy |
Xenetic Biosciences Inc (XBIO) 最新ニュース
Xenetic Biosciences Reports Improved Q1 2025 Results - TipRanks
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan
Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post
Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com
Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board - ACCESS Newswire
Xenetic Biosciences, Inc. to Present at BIO Investor Forum - ACCESS Newswire
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM) - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire
Xenetic Biosciences Inc (XBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):